← Back to Clinical Trials
Recruiting NCT06051318

NCT06051318 Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06051318
Status Recruiting
Phase
Sponsor BiomeHub Biotechnology Company
Condition Glucose Metabolism Disorders
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-06-06
Primary Completion 2024-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Standardized breakfast AStandardized breakfast B

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-06-06 with a primary completion date of 2024-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

When all the food we eat is digested, it will increase blood glucose. Two people can have different glucose blood levels to the same food and one reason can be bacteria live in our gut. There are more than a thousand bacteria species in our gastrointestinal tract that have an important role in the proper functioning of our body, so our gut microbiome is a key piece for our nutrition and blood glucose control. Nowadays, one of the major public health concerns is the rise of people with diabetes (a disease characterized by an increase in blood glucose) and the increase in obesity, in which one of several risks is diabetes. There are multiple reasons for people develop those diseases, however, some care on diet management can prevent, delay, or improve the effects of these illnesses. Therefore, this study proposes studying the blood glucose variation between healthy volunteers and if there is a relationship between that variation and the intestinal bacteria present. These results can help doctors and nutritionists elaborate a personalized diet for people who need blood glucose level control. The investigators are recruiting volunteers aged 18 to 60, healthy, living at Florianopolis and the surroundings to participate in this crossover randomized N-of-1 study. The participants must collect fecal samples. After collection, the participants will meet the investigators and receive a kit containing ten standardized breakfasts, with two kinds of muffins, and a kit containing a glucose monitor (Abbott Freestyle Libre-CE marked) to monitor their blood sugar levels. The volunteers must have breakfast with the standardized meals and monitor the fasting glucose blood and postprandial glucose blood levels for ten consecutive days. Besides, they must take notes (like a diet diary) about all the food they ingest during the day in ten days of the study.

Eligibility Criteria

Inclusion Criteria: * BMI \> 18.5 and \< 30 * Willing to use an intradermal continuous glucose monitoring sensor during the 10-day study * Own a mobile phone with NFC technology * Willing to provide a fecal swab sample and a stool sample * Understanding, agreement, and signing of the approved Informed Consent Form (ICF) by the Ethics Committee (CEP) Exclusion Criteria: * Pregnant or lactating women * Diagnosis of any gastrointestinal disorder or disease (Irritable Bowel Syndrome, Ulcerative Colitis, Crohn's Disease) * Intolerance or allergy to any diet ingredient * Autoimmune disorder (Lupus, Type 1 Diabetes, Celiac Disease) or infectious disease * Diabetes diagnosis * Cancer diagnosis, acute myocardial infarction, or stroke in the last 6 months * Use of hypoglycemic medication * Use of proton pump inhibitors, immunosuppressants, or antimicrobials in the last 3 months * Use of laxative medications in the last 30 days * Underwent invasive procedures or surgery in the last 6 months * Admission to ICU in the last 2 years * Participation in any experimental study or ingestion of any experimental drug within twelve months prior to the start of this study, in accordance with RDC 251/97 * Inability to read and understand the informed consent form

Contact & Investigator

Central Contact

Luiz Felipe V. de Oliveira, PhD

✉ felipe@biome-hub.com

📞 +554830121322

Principal Investigator

Caetana P. Zamparette, PhD

STUDY CHAIR

Researcher fellow

Frequently Asked Questions

Who can join the NCT06051318 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Glucose Metabolism Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06051318 currently recruiting?

Yes, NCT06051318 is actively recruiting participants. Contact the research team at felipe@biome-hub.com for enrollment information.

Where is the NCT06051318 trial being conducted?

This trial is being conducted at Florianópolis, Brazil.

Who is sponsoring the NCT06051318 clinical trial?

NCT06051318 is sponsored by BiomeHub Biotechnology Company. The principal investigator is Caetana P. Zamparette, PhD at Researcher fellow. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology